A Tutorial on the Development of a Physiologically Inspired <scp>PKRO</scp> Model for Monoclonal Antibodies

Modeling and simulations are indispensable tools to describe pharmacokinetics (PK) and pharmacodynamics to support monoclonal antibody (mAb) development. The linear PK of mAbs is commonly described by a 2-compartment PK model, while the nonlinear PK often observed at low doses is described by target mediated drug disposition (TMDD) models. Since target binding is the primary pharmacology of mAbs and receptor occupancy (RO) could impact PK through TMDD, it is desirable to have a simple mechanistic model to simultaneously describe both PK, including TMDD, and RO at the site of action (SoA). In this tutorial, we introduce a physiologically inspired PKRO (piPKRO) model for mAbs targeting membrane receptors. The linear PK part (referred to as the piPK model) is modified from the classical 2-compartment PK model to include using the physiological compartment volumes, adding drug clearance in extravascular compartments, describing mAb concentration in tissues reflecting measured partition coefficients, and target expression and drug binding based on the location of target expression. A few macroparameters including P<sub>dist</sub> (partition coefficient) and t<sub>dist</sub> (distribution half-time) are introduced to provide an intuitive understanding of the mAb distribution. Case studies of applying the model to real world data are provided. Analysis with the piPKRO model suggests that local drug depletion could occur due to significant target mediated drug clearance at the SoA in combination with relatively slow drug distribution. This local drug depletion can lead to much lower RO at the SoA compared to RO in the central compartment and subsequently impact efficacious dose predictions.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2025-12-14
DOI
https://doi.org/10.1002/psp4.70160
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies

Georgi I. Kapitanov, Joshua F. Apgar, Diana H. Marcantonio, Timothy R. Lezon et al.
CPT Pharmacometrics & Systems Pharmacology
Monoclonal and Polyclonal Antibodies Research
article

A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies

Georgi I. Kapitanov, Joshua F. Apgar, Diana H. Marcantonio, Timothy R. Lezon, Fei Hua, David Flowers
article en

Abstract

Modeling and simulations are indispensable tools to describe pharmacokinetics (PK) and pharmacodynamics to support monoclonal antibody (mAb) development. The linear PK of mAbs is commonly described by a 2-compartment PK model, while the nonlinear PK often observed at low doses is described by target mediated drug disposition (TMDD) models. Since target binding is the primary pharmacology of mAbs and receptor occupancy (RO) could impact PK through TMDD, it is desirable to have a simple mechanistic model to simultaneously describe both PK, including TMDD, and RO at the site of action (SoA). In this tutorial, we introduce a physiologically inspired PKRO (piPKRO) model for mAbs targeting membrane receptors. The linear PK part (referred to as the piPK model) is modified from the classical 2-compartment PK model to include using the physiological compartment volumes, adding drug clearance in extravascular compartments, describing mAb concentration in tissues reflecting measured partition coefficients, and target expression and drug binding based on the location of target expression. A few macroparameters including P<sub>dist</sub> (partition coefficient) and t<sub>dist</sub> (distribution half-time) are introduced to provide an intuitive understanding of the mAb distribution. Case studies of applying the model to real world data are provided. Analysis with the piPKRO model suggests that local drug depletion could occur due to significant target mediated drug clearance at the SoA in combination with relatively slow drug distribution. This local drug depletion can lead to much lower RO at the SoA compared to RO in the central compartment and subsequently impact efficacious dose predictions.

CPT Pharmacometrics & Systems PharmacologyVol. 15(2)
Certara (United States) (US)
Openalex Percentile: Top 45%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.